Trials / Recruiting
RecruitingNCT07246213
CAYA Cancer Retrospective Cohort Study
Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Retrospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 18,000 (estimated)
- Sponsor
- Resonance, Inc. · Academic / Other
- Sex
- All
- Age
- 0 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies. Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare. This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.
Conditions
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Young Adult Cancer
- Adolescent Cancer
- Childhood Cancers
- Acute Lymphoblastic Leukemia (ALL)
- Lymphoblastic Lymphoma (LBL)
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Retrospective Medical Record Review | This study involves retrospective review of medical records of pediatric, adolescent, and young adult cancer patients (ages 0-21 years) treated at participating oncology centers in Guatemala, Honduras, El Salvador, Armenia, and Tanzania. No experimental drug, device, or behavioral intervention is being administered. Data abstraction will be performed to assess treatment failure, therapy-related toxicities, and clinical outcomes. |
Timeline
- Start date
- 2025-06-04
- Primary completion
- 2028-06-04
- Completion
- 2028-12-04
- First posted
- 2025-11-24
- Last updated
- 2025-12-19
Locations
5 sites across 4 countries: Armenia, El Salvador, Guatemala, Honduras
Source: ClinicalTrials.gov record NCT07246213. Inclusion in this directory is not an endorsement.